Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | OGG1 | O15527 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | HTR2B | P41595 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | SCN1A | P35498 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25268253 | 1.00 | BTN3A1 (0.35) | BTN3A1KMT2AOGG1CYP2D6CYP1A2 | |
| SCHEMBL29637567 | 0.91 | BTN3A1 (0.38) | BTN3A1OGG1CYP2D6CYP1A2ADRB2 | |
| SCHEMBL29895522 | 0.90 | BTN3A1 (0.41) | BTN3A1OGG1ALDH1A1LMNAHTT | |
| SCHEMBL28986476 | 0.90 | BTN3A1 (0.41) | BTN3A1OGG1ALDH1A1LMNAHTT | |
| SCHEMBL23044633 | 0.87 | MEN1 (0.39) | BTN3A1KMT2AOGG1NR2E1ALDH1A1 | |
| SCHEMBL20587649 | 0.85 | BTN3A1 (0.42) | BTN3A1KMT2AALDH1A1LMNAMAPK1 | |
| SCHEMBL20833545 | 0.85 | BTN3A1 (0.42) | BTN3A1KMT2AALDH1A1LMNAMAPK1 | |
| SCHEMBL22065060 | 0.85 | BTN3A1 (0.42) | BTN3A1KMT2AALDH1A1LMNAMAPK1 | |
| SCHEMBL13469494 | 0.85 | HTT (0.39) | BTN3A1KMT2AOGG1ALDH1A1LMNA | |
| SCHEMBL30435500 | 0.85 | BTN3A1 (0.42) | BTN3A1KMT2AALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-112513061-B | 4' -Thio-nucleotides and-nucleoside prodrugs for treating cancer | 南方研究院 | 2025-01-24 | — | — | CN | disclosed |
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11939347-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4209498-A1 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | Southern Research Institute (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023102472-A1 | ANTIVIRAL PRODRUGS AND FORMULATIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-4172160-A2 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-115996928-A | 1' -cyanonucleoside analogs and uses thereof | 吉利德科学公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230040586-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | TYMP, PNP, DUT | BTN3A1 3427/4885KMT2A 4070/4885OGG1 165/4885 |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | BTN3A1 3685/4885KMT2A 4054/4885OGG1 160/4885 |
| US-20230040586-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | TYMP, PNP, DUT | BTN3A1 3427/4885KMT2A 4070/4885OGG1 165/4885 |
| US-11939347-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | BTN3A1 3685/4885KMT2A 4054/4885OGG1 160/4885 |
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | PNP, SLC28A1, SLC29A1 | BTN3A1 3686/4885KMT2A 3840/4885OGG1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.